Search

Search Constraints

You searched for: Author/Creator Castellano, Daniel

Search Results

1. A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide. Issue 4 (23rd December 2022)

2. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. (November 2022)

3. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Issue 4 (April 2021)

4. Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. Issue 1 (December 2015)

5. Association of prior local therapy and outcomes with programmed‐death ligand‐1 inhibitors in advanced urothelial cancer. (25th October 2021)

6. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Issue 10031 (7th May 2016)

7. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Issue 10122 (24th February 2018)

10. Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. (September 2014)